Medication Compliance and Adherence in Schizophrenia: Raising the Bar

Title:

Medication Compliance and Adherence in Schizophrenia: Raising the Bar

Topic: Psychiatry
Relevant Terms: Patient Adherence, Patient Compliance, Schizophrenia
Primary Audience: Primary care providers (MDs/ DOs/ NPs/ PAs), Psychiatrists
Launch Date: 14-Jun-13
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Medication Compliance and Adherence in Schizophrenia: Raising the Bar

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Integrate evidence-based interventions for improved schizophrenia treatment adherence and compliance into daily practice
  2. Discuss efficacy, safety and PK data for long-acting injectable antipsychotics (LAI) for schizophrenia
  3. Select eligible patients for LAI intervention, and begin the dialog regarding LAI use

    Faculty

    John Lauriello, MD
    Chancellor's Chair of Excellence in Psychiatry
    Medical Director of the Missouri Psychiatric Center

    Columbia, MO
    Alejandro (Alex) Kopelowicz, MD
    Professor and Vice-Chair, Department of Psychiatry and Biobehavioral Sciences
    David Geffen School of Medicine at UCLA
    Medical Director of the San Fernando Mental Health Center (SFMHC)
    Chief of Psychiatry at Olive View
    UCLA Medical Center
    Los Angeles, CA
    Peter Weiden, MD
    Professor of Psychiatry and Director of the Psychotic Disorders Program
    Center for Cognitive Medicine
    University of Illinois Medical Center
    Chicago, IL
    TARGET AUDIENCE
    This activity has been designed to meet the needs of psychiatrists and primary care physicians involved in the care of patients with mental health issues. 

    DISCLOSURE POLICY STATEMENT
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty Disclosures
    • John Lauriello, MD, has affiliations with Otsuka (Advisory Board-payment made to University of Missouri as a contract to the department of psychiatry); and Janssen (DSMB-payment made to University of Missouri as a contract to the department of psychiatry).
    • Alex Kopelowicz, MD, has no affiliations with commercial interests to disclose.
    • Peter J. Weiden, MD, has affiliations with Delpor, Johnson & Johnson (Janssen), Lundbeck, Otsuka USA, Merck, Novartis, Sunovion, and Genentech/Roche (Consultant); Johnson & Johnson (Janssen), Merck, Novartis, and Sunovion (Speaker's Bureau); Genentech/Roche, Johnson & Johnson (Janssen), Novartis, Sunovion, and Neurocrine (Grant Support); and Delpor (Stockholder).

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    RMEI, LLC
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
    • Cynthia M. Kunzer has no affiliations with commercial interests to disclose.

    Postgraduate Institute for Medicine
    The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

    DISCLOSURE OF UNLABELED USE

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    PHYSICIAN CONTINUING EDUCATION
    ACCREDITATION STATEMENT
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Estimated time to complete - 30 minutes
    Medium: Internet

    FEE INFORMATION
    There is no fee for this educational activity.

    COMMERCIAL SUPPORT
    This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine. RMEI gratefully acknowledges an educational grant from Otsuka America Pharmaceutical, Inc. in support of this CME activity.

    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.50 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
       
    COURSE VIEWING REQUIREMENTS
    Google Chrome 18.0+ for Windows, Mac, or Linux
    Internet Explorer 8.0+ for Windows
    Firefox 13.0+ for Windows, Mac, or Linux
    Safari 4.0+ for Mac